Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients.

@article{Urup2016AngiotensinogenAH,
  title={Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients.},
  author={Thomas Urup and Signe Regner Michaelsen and Lars R\onn Olsen and Anders Toft and Ib Jarle Christensen and Kirsten Grunnet and Ole Winther and Helle Broholm and Michael Kosteljanetz and Shohreh Issazadeh-Navikas and Hans Skovgaard Poulsen and Ulrik Lassen},
  journal={Molecular oncology},
  year={2016},
  volume={10 8},
  pages={1160-8}
}
BACKGROUND Bevacizumab combination therapy is among the most frequently used treatments in recurrent glioblastoma and patients who achieve response to bevacizumab have improved survival as well as quality of life. Accordingly, the aim of this study was to identify predictive biomarkers for bevacizumab response in recurrent glioblastoma patients. METHODS The study included a total of 82 recurrent glioblastoma patients treated with bevacizumab combination therapy whom were both response and… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2015

Combining two strategies to improve perfusion and drug delivery in solid tumors.

Proceedings of the National Academy of Sciences of the United States of America • 2013

Similar Papers

Loading similar papers…